Ann: Trading Halt, page-16

hatmopit, that is not correct. the trial was powered to be statistically significant with 1,100 patients over 3 years. In fact with 500 patients for 1 year ( i.e. 1/6th of the observations) the results showed that Ldex was better than tape measure with 87% confidence. Ok, its not the desired 95% but every statistician knows it will get there with either the 500 2 year data or the 1,100 1 year data or both. NCCN and private payors understand this , but of course that is no guarantee they will both come up trumps for LDex in this round. The market is hating the uncertainty as to the timing of a decision